Johnson & Johnson (NYSE:JNJ) is Hunter Perkins Capital Management LLC’s 8th Largest Position

Hunter Perkins Capital Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 98,130 shares of the company’s stock after selling 2,520 shares during the quarter. Johnson & Johnson comprises approximately 3.0% of Hunter Perkins Capital Management LLC’s portfolio, making the stock its 8th biggest holding. Hunter Perkins Capital Management LLC’s holdings in Johnson & Johnson were worth $14,192,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Vinva Investment Management Ltd increased its position in shares of Johnson & Johnson by 6.8% during the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after buying an additional 7,110 shares during the period. Financial Counselors Inc. increased its holdings in Johnson & Johnson by 5.3% during the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock worth $29,996,000 after acquiring an additional 9,309 shares during the period. Meridian Investment Counsel Inc. lifted its stake in Johnson & Johnson by 19.6% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock worth $3,667,000 after purchasing an additional 3,710 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after purchasing an additional 102,502 shares during the period. Finally, Lord Abbett & CO. LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $69,859,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.6 %

JNJ opened at $151.27 on Thursday. The firm has a market capitalization of $364.20 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The business has a 50 day simple moving average of $147.76 and a two-hundred day simple moving average of $156.13. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the business posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.28%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Bank of America lowered their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $170.44.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.